Kura Oncology (KURA) Other Non-Current Assets (2014 - 2026)
Kura Oncology (KURA) posted quarterly Other Non-Current Assets of $14.0 million for Q1 2026, up 54.09% year-over-year from $9.1 million in Q1 2025, and down 3.8% quarter-over-quarter from $14.5 million in Q4 2025.
Kura Oncology (KURA) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Other Non-Current Assets for 13 consecutive years, with $14.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 54.09% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (up 54.09% YoY), while the FY2025 annual figure was $14.5 million, up 85.38% from the prior year.
- Other Non-Current Assets retreated to $14.0 million in Q1 2026 per KURA's latest filing, from $14.5 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $14.5 million in Q4 2025 and bottomed at $210000.0 in Q1 2022.
- Historically, Other Non-Current Assets has averaged $6.7 million across 5 years, with a median of $7.6 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets changed 0.0% — and 2024, when it surged 3435.71%.
- Kura Oncology's Other Non-Current Assets stood at $3.5 million in 2022, then soared by 117.32% to $7.6 million in 2023, then advanced by 3.2% to $7.8 million in 2024, then surged by 85.38% to $14.5 million in 2025, then fell by 3.8% to $14.0 million in 2026.
- Business Quant data shows KURA's Other Non-Current Assets at $14.0 million in Q1 2026, $14.5 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 13.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.73 Mn |
| Mar 31, 2026 | 13.99 Mn |
| Dec 31, 2025 | 14.54 Mn |
| Sep 30, 2025 | 13.78 Mn |
| Jun 30, 2025 | 10.57 Mn |
| Mar 31, 2025 | 9.08 Mn |
| Dec 31, 2024 | 7.85 Mn |
| Sep 30, 2024 | 8.23 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Mar 31, 2024 | 7.67 Mn |
| Dec 31, 2023 | 7.60 Mn |
| Sep 30, 2023 | 4.52 Mn |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 3.50 Mn |
| Sep 30, 2022 | 210,000.00 |
| Jun 30, 2022 | 210,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Dec 31, 2021 | 210,000.00 |
| Sep 30, 2021 | 210,000.00 |